Nicholas Hoffman & Company LLC. bought a new position in Baxter International Inc. (NYSE:BAX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 31,103 shares of the medical instruments supplier's stock, valued at approximately $907,000.
A number of other hedge funds also recently made changes to their positions in BAX. CKW Financial Group lifted its stake in shares of Baxter International by 19.3% in the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier's stock valued at $77,000 after purchasing an additional 425 shares during the last quarter. Farther Finance Advisors LLC raised its position in Baxter International by 23.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,519 shares of the medical instruments supplier's stock worth $96,000 after purchasing an additional 475 shares during the period. LRI Investments LLC lifted its stake in Baxter International by 60.8% in the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier's stock worth $59,000 after purchasing an additional 590 shares during the last quarter. Greenleaf Trust lifted its stake in Baxter International by 10.0% in the third quarter. Greenleaf Trust now owns 9,491 shares of the medical instruments supplier's stock worth $360,000 after purchasing an additional 859 shares during the last quarter. Finally, Fortitude Family Office LLC purchased a new position in shares of Baxter International during the third quarter valued at approximately $38,000. 90.19% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. StockNews.com cut shares of Baxter International from a "buy" rating to a "hold" rating in a research report on Monday, November 11th. Stifel Nicolaus dropped their price objective on Baxter International from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Monday, November 11th. Barclays began coverage on Baxter International in a research report on Thursday. They set an "overweight" rating and a $39.00 target price for the company. Finally, Citigroup decreased their price objective on Baxter International from $37.00 to $35.00 and set a "neutral" rating for the company in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $39.40.
Check Out Our Latest Stock Report on BAX
Baxter International Stock Performance
Shares of NYSE:BAX traded up $2.62 during trading on Thursday, hitting $33.44. 10,687,975 shares of the stock traded hands, compared to its average volume of 4,856,285. Baxter International Inc. has a 52-week low of $28.33 and a 52-week high of $44.01. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. The company has a market cap of $17.07 billion, a price-to-earnings ratio of 167.18, a P/E/G ratio of 9.95 and a beta of 0.61. The company has a fifty day moving average price of $30.52 and a two-hundred day moving average price of $34.15.
Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. As a group, equities analysts predict that Baxter International Inc. will post 1.83 EPS for the current year.
Baxter International Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be paid a dividend of $0.17 per share. The ex-dividend date is Friday, February 28th. This represents a $0.68 annualized dividend and a yield of 2.03%. Baxter International's payout ratio is 340.02%.
Baxter International Profile
(
Free Report)
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Featured Articles
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
